Daiichi Sankyo
↗Chuo, Tokyo, Japan
Daiichi Sankyo is a global pharmaceutical company established in 2005 through the merger of two century-old Japanese pharmaceutical companies: Sankyo Company, Limited (founded 1899) and Daiichi Pharmaceutical Company, Limited (founded 1915). The company is dedicated to its Purpose: "To contribute to the enrichment of quality of life around the world." Headquartered in Tokyo/Chuo, Japan, Daiichi Sankyo has evolved into Japan's second-largest pharmaceutical company with a strong focus on innovative therapies for cancer and cardiovascular diseases. The company operates in more than 20 countries globally with approximately 19,765 employees, positioning itself as a leader in oncology through its proprietary DXd antibody-drug conjugate (ADC) platform technology.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology biotech, Cardiovascular therapeutics
SIZE & FINANCIALS
Employees:10000+
Revenue:$1.8B-$2.0B JPY (~$12.5B-$13.5B USD equivalent)
Founded:2005
Ownership:public
Status:operating
STOCK
Exchange:Tokyo Stock Exchange (TSE) / Over-the-counter (OTC US)
Ticker:4568 (TSE) / DSNKY (OTC US)
Market Cap:$42.58B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 and Commercial (ENHERTU and DATROWAY approved)
Modalities:Antibody-Drug Conjugate (ADC/DXd), Small molecule, Monoclonal antibody, Nucleic acid therapy, Gene therapy
Active Trials:60
Trial Phases:-
FDA Approvals:4
EMA Approvals:3
CORPORATE STRUCTURE
Subsidiaries:Daiichi Sankyo, Inc. (USA, headquartered in Basking Ridge, New Jersey), American Regent, Inc. (subsidiary), Daiichi Sankyo Europe GmbH (Munich, Germany)
Key Partnerships:AstraZeneca - Global development and commercialization of ENHERTU (HER2-DXd) and Datopotamab deruxtecan (TROP2-DXd), both approved, Merck - Global development and commercialization collaboration for three DXd ADCs: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), with $4B upfront payment and $22B total deal value, Glycotope - IP acquisition of gatipotuzumab (DS-3939) in December 2024
COMPETITION
Position:Leader (in ADC platform technology and HER2+ breast cancer)
Competitors:Pfizer, Johnson & Johnson, Novartis, Roche (F. Hoffmann-La Roche Ltd), AstraZeneca, Merck & Co., Eli Lilly and Company, Takeda Pharmaceutical +1 more
LEADERSHIP
Key Executives:
Hiroyuki Okuzawa - Chief Executive Officer (CEO)
Sunao Manabe - Executive Chairperson, Representative Director
Koji Ogawa - Chief Financial Officer (CFO), Head of Global Corporate Planning & Management
Ken Keller - President and Chief Executive Officer - Daiichi Sankyo, Inc. (US subsidiary), Head of Global Oncology Business
LINKS
Website:daiichisankyo.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Daiichi Sankyo. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.